Chief medical officer, ML Bio Solutions
Raising Awareness to Improve Early Diagnosis and Treatment of Duchenne Muscular Dystrophy: Douglas Sproule, MD, MSc
The chief medical officer at ML Bio Solutions, an affiliate of BridgeBio, talked about the importance of awareness for neuromuscular diseases such as Duchenne muscular dystrophy and why a timely diagnosis can make a profound difference in a patient’s life. [WATCH TIME: 3 minutes]
Potential FDA Accelerated Approval for Limb-Girdle Muscular Dystrophy 2I/R9 Therapy: Douglas Sproule, MD, MSc
The chief medical officer at ML Bio Solutions, an affiliate of BridgeBio, discussed how promising conversations between researchers and regulatory authorities suggest a potential pathway for accelerated approval for limb-girdle muscular dystrophy type 2I/R9. [WATCH TIME: 3 minutes]
Balancing Safety and Efficacy in Developing Therapeutic for Rare Neuromuscular Diseases: Douglas Sproule, MD, MSc
The chief medical officer at ML Bio Solutions, an affiliate of BridgeBio, discussed developing therapies for rare neuromuscular diseases such as limb girdle muscular dystrophy 2I/R9 and the unique challenges that occur in clinical trial settings. [WATCH TIME: 5 minutes]
Advancing BBP-418 in Phase 3 Settings as Potential Limb Girdle Muscular Dystrophy Treatment: Douglas Sproule, MD, MSc
The chief medical officer at ML Bio Solutions, an affiliate of BridgeBio, talked about the significant progress of investigational agent BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9. [WATCH TIME: 3 minutes]
The Use of Molecular Testing in Limb Girdle Muscular Dystrophy: Douglas Sproule, MD, MSc
The chief medical officer at ML Bio Solutions spoke about the advances in neuromuscular diseases such as limb girdle muscular dystrophy at the 2023 MDA Conference. [WATCH TIME: 3 minutes]
